Osteoporosis in patients with inflammatory bowel disease: Risk factors, prevention, and treatment

Reviews in Gastroenterological Disorders

Volumn 6, Issue 2, 2006, Pages 63-71

  Katz, Seymour ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c ST FRANCIS HOSPITAL   (United States)

Author keywords

Bisphosphonate; Crohn's disease; Glucocorticoids; Inflammatory bowel disease; Osteoporosis; Ulcerative colitis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; GLUCOCORTICOID; INFLIXIMAB; NOSE SPRAY; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; TESTOSTERONE; VITAMIN D;

BODY MASS; BONE DENSITY; BONE MASS; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DRUG DOSE REGIMEN; DRUG METABOLISM; ENTERITIS; FAMILY HISTORY; FRAGILITY FRACTURE; HIGH RISK PATIENT; HORMONE DEFICIENCY; HUMAN; MALABSORPTION; META ANALYSIS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPOROSIS; RISK FACTORS;

EID: 33744813258     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
2. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
3. American Gastroenterological Association. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:791-794.
4. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133: 795-799.
5. Arden NK, van Staa T, Cooper C, et al. Inflammatory bowel disease and the risk of fracture [abstract]. Rheumatology (Oxford). 2003; 42(suppl 1): 115.
6. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1: 465-473.
7. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123: 468-475.
8. Shen B, Fazio V, Remzi F, et al. Risk factors of osteoporosis in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100:5303.
9. Bernstein CN, Leslie WD. Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;19:941-952.
10. Lichtenstein G. Management of bone loss in inflammatory bowel disease. Semin Gastrointest Dis. 2001;12:275-283.
11. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Meade, NJ: Excerpta Medica; 2003.
12. de Jong DJ, Carstens FH, Mannaerts L, et al. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol. 2002;97:2011-2015.
13. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol. 1999;94:824-828.
14. Habtezion A, Silverberg MS, Parkes R, et al. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis. 2002;8:87-92.
15. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-739.
16. Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919-923.
17. Lane NE. An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2001; 27:235-253.
18. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
19. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004; 53:251-255.
20. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13:777-787.
21. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
22. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3: 113-121.
23. Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med. 2004;95:469-480.
24. Bernstein CN, Katz S. Osteoporosis and inflammatory bowel disease. A guide to diagnosis and management for the gastroenterologist. American College of Gastroenterology. Available at: http://www.acg.gi.org. Accessed March 15, 2004.
25. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol. 1999; 94:878-883.
26. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001; 44:1496-1503.
27. Procter & Gamble Pharmaceuticals. Actonel (risedronate sodium). Full prescribing information. Cincinnati, OH: Procter & Gamble Pharmaceuticals; 2003.
28. Merck & Co. Fosamax (alendronate sodium). Full prescribing information. West Point, PA: Merck & Co; 2003.
29. Greenspan SL, Bone G 3rd, Schnitzer TJ, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of post-menopausal osteoporosis. J Bone Miner Res. 2002;17:1988-1996.
30. Schnitzer T, Bone H, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12:1-12.
31. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103-111.
32. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res. 2001;16:104-112.
33. Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int. 1997;61: 266-271.
34. Novartis. Aredia (pamidronate). Full prescribing information. East Hanover, NJ: Novartis; 2002.
35. Siffledeen JS, Fedorak RN, Siminioski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density of Crohn's disease. Clin Gastroenterol Hepatol. 2005;3:122-132.
36. Bernstein CN. Limiting fracture risk in Crohn's disease: is there anything better than calcium and vitamin D? Clin Gastroenterol Hepatol. 205;3:110-112.
37. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15:1006-1013.
38. Reid IR. Preventing glucocorticoid-induced osteoporosis. Z Rheumatol. 2000;59:97-102.
39. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-285.
40. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin. 2004;20:433-439.
41. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
42. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established post-menopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
43. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120-126.
44. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc. 2002;77:262-270.
45. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-299.
46. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211.
47. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333:1437-1443.
48. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
49. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
50. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-4124.
51. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch Intern Med. 2000;160:517-525.
52. Novartis Pharmaceuticals. Miacalcin (calcitonin salmon). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2003.
53. Cranney A, Welch V, Adachi J, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis [Cochrane Methodology Review]. In: The Cochrane Library. Chichester, UK: John Wiley & Sons; 2003.
54. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut. 1993;34:1543-1546.
55. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738.
56. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18:171-177.
57. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res. 1997;12:472-478.
58. Robinson RJ, Iqbal SJ, Al-Azzawi F, et al. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther. 1998;12:21-25.
59. Eli Lilly and Company. Evista (raloxifene HCl). Full prescribing information. Indianapolis, IN: Eli Lilly and Company; 2002.
60. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282: 637-645.
61. Eli Lilly and Company. Forteo (teriparatide). Full prescribing information. Indianapolis, IN: Eli Lilly and Company; 2002.
62. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
63. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998;102:1627-1633.
64. Abu-Amer Y, Erdmann J, Alexopoulou L, et al. Tumor necrosis factor types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem. 2000;275:27303-27306.
65. Zhang H, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem. 2001;276:563-568.
66. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease. The ACCENT I randomized trial. Lancet. 2003; 359:1541-1549.
67. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
68. Ryan BM, Russell MGVM, Schranger SL, et al. Effect of anti tumor necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851-857.
69. Blustein M, Irwin S, Greenberg GR. Maintenance infliximab is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031-2035.